Aydin, P. Et Al. 2022. Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway. Lung , vol.200, no.5 , 561-572.

Aydin, P., Magden, Z. B. A., Uzuncakmak, S. K., HALICI, H., Akgun, N., Mendil, A. S., ... Mokhtare, B.(2022). Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway. Lung , vol.200, no.5, 561-572.

Aydin, Pelin Et Al. "Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway," Lung , vol.200, no.5, 561-572, 2022

Aydin, Pelin Et Al. "Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway." Lung , vol.200, no.5, pp.561-572, 2022

Aydin, P. Et Al. (2022) . "Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway." Lung , vol.200, no.5, pp.561-572.

@article{article, author={Pelin Aydin Et Al. }, title={Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway}, journal={Lung}, year=2022, pages={561-572} }